Dapivirine
Dapivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the prevention of HIV/AIDS. It is primarily administered through a vaginal ring, which is designed to provide sustained release of the drug over a period of time.
Mechanism of Action[edit]
Dapivirine works by inhibiting the activity of the reverse transcriptase enzyme, which is essential for the replication of HIV. By blocking this enzyme, dapivirine prevents the virus from multiplying and spreading within the body.
Development and Approval[edit]
Dapivirine was developed by the International Partnership for Microbicides (IPM). The dapivirine vaginal ring has undergone extensive clinical trials to evaluate its safety and efficacy. In 2020, the European Medicines Agency (EMA) gave a positive opinion on the dapivirine vaginal ring, and it has been approved for use in several countries.
Clinical Trials[edit]
Several clinical trials have been conducted to assess the effectiveness of dapivirine in preventing HIV infection. Notable among these are the ASPIRE and The Ring Study trials, which demonstrated a significant reduction in the risk of HIV infection among women who used the dapivirine vaginal ring.
Usage[edit]
The dapivirine vaginal ring is inserted into the vagina and left in place for a month, after which it is replaced with a new ring. This method of delivery ensures a steady release of the drug, maintaining effective drug levels in the vaginal tissues.
Side Effects[edit]
Common side effects of dapivirine include mild to moderate vaginal irritation, discomfort, and discharge. Serious side effects are rare but can include allergic reactions.
Advantages[edit]
The dapivirine vaginal ring offers several advantages over other forms of HIV prevention, such as oral pre-exposure prophylaxis (PrEP). These include:
- Long-acting protection
- Reduced need for daily adherence
- Discreet use
Future Directions[edit]
Research is ongoing to explore the potential of dapivirine in other forms of delivery, such as injectable formulations and topical gels. Additionally, studies are being conducted to evaluate its effectiveness in different populations, including adolescents and pregnant women.
See Also[edit]
- HIV/AIDS
- Non-nucleoside reverse transcriptase inhibitor
- Pre-exposure prophylaxis
- International Partnership for Microbicides
References[edit]
External Links[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
